Multiple Myeloma – Sanofi LPS18183
The primary purpose of this study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in combination with weekly carfilzomib and dexamethasone (Kd) in adult participants with RRMM having received 1 to 3 prior lines of therapy.
Inclusion Criteria:
- Must be 18 years or older
- Participants must have a documented diagnosis of MM
- Participants with relapsed and/or refractory MM with at least 1 prior line of therapy and no more than 3 prior lines of therapy
- Capable of giving signed informed consent
Complete the form to get connected and someone from our team will reach out soon to help determine your eligibility.
